BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, Largent-Milnes TM, Vanderah TW. Glial neuroimmune signaling in opioid reward. Brain Res Bull 2020;155:102-11. [PMID: 31790721 DOI: 10.1016/j.brainresbull.2019.11.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Larsen PA. Single-cell sequencing of Entorhinal Cortex Reveals Wide-Spread Disruption of Neuropeptide Networks in Alzheimer’s Disease.. [DOI: 10.1101/2022.11.14.516160] [Reference Citation Analysis]
2 Yen E, Madan N, Tarui T, Kaneko-tarui T, Breeze JL, Davis JM, Maron JL. Sex-specific inflammatory and white matter effects of prenatal opioid exposure: a pilot study. Pediatr Res 2022. [DOI: 10.1038/s41390-022-02357-5] [Reference Citation Analysis]
3 Leyrer-jackson JM, Acuña AM, Olive MF. Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update. Expert Opinion on Pharmacotherapy 2022. [DOI: 10.1080/14656566.2022.2140039] [Reference Citation Analysis]
4 Martin LF, Cheng K, Washington SM, Denton M, Goel V, Khandekar M, Largent-milnes TM, Patwardhan A, Ibrahim MM. Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain. The Journal of Pain 2022. [DOI: 10.1016/j.jpain.2022.10.011] [Reference Citation Analysis]
5 Rezaei K, Sheikholeslami M, Salimi-sabour E, Lotfali E, Parvardeh S. Attenuation of Morphine Dependence by Ganoderma lucidum Extract in Mice. Jundishapur J Nat Pharm Prod 2022;In Press. [DOI: 10.5812/jjnpp-123164] [Reference Citation Analysis]
6 Ray MH, Williams BR, Kuppe MK, Bryant CD, Logan RW. A Glitch in the Matrix: The Role of Extracellular Matrix Remodeling in Opioid Use Disorder. Front Integr Neurosci 2022;16:899637. [PMID: 35757099 DOI: 10.3389/fnint.2022.899637] [Reference Citation Analysis]
7 Butelman ER, Kreek MJ. Neurobiological Mechanisms in Substance Use. Genetics of Substance Use 2022. [DOI: 10.1007/978-3-030-95350-8_2] [Reference Citation Analysis]
8 Shen W, Mei D, Liu Y, Zhou W. Cognitive Enhancers: What They Are and How They Are Used in Heroin Addiction. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-92392-1_94] [Reference Citation Analysis]
9 Büttner A. Neurobiologische Grundlagen des Drogenmissbrauchs. Neuropathologie des Drogenmissbrauchs 2022. [DOI: 10.1007/978-3-031-13619-1_2] [Reference Citation Analysis]
10 Xu Y, Chen R, Zhi F, Sheng S, Khiati L, Yang Y, Peng Y, Xia Y. δ-opioid Receptor, Microglia and Neuroinflammation. Aging and disease 2022. [DOI: 10.14336/ad.2022.0912] [Reference Citation Analysis]
11 Green JM, Sundman MH, Chou Y. Opioid-induced microglia reactivity modulates opioid reward, analgesia, and behavior. Neuroscience & Biobehavioral Reviews 2022. [DOI: 10.1016/j.neubiorev.2022.104544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Shen W, Mei D, Liu Y, Zhou W. Cognitive Enhancers: What They Are and How They Are Used in Heroin Addiction. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_94-1] [Reference Citation Analysis]
13 Leduc-Pessah H, Trang T. Tackling the opioid crisis: Novel mechanisms and clinical perspectives. J Neurosci Res 2021. [PMID: 34672010 DOI: 10.1002/jnr.24964] [Reference Citation Analysis]
14 Ihezie SA, Dafny N. Prevention of Opioid Addiction. J Biomed Res Environ Sci 2021;2:731-740. [DOI: 10.37871/jbres1304] [Reference Citation Analysis]
15 Zhang H, Lipinski AA, Liktor-Busa E, Smith AF, Moutal A, Khanna R, Langlais PR, Largent-Milnes TM, Vanderah TW. The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area. Front Pharmacol 2021;12:632757. [PMID: 33953672 DOI: 10.3389/fphar.2021.632757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Namba MD, Leyrer-Jackson JM, Nagy EK, Olive MF, Neisewander JL. Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities. Front Neurosci 2021;15:650785. [PMID: 33935636 DOI: 10.3389/fnins.2021.650785] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
17 Büttner A. Neurobiological Basis of Drug Abuse. Neuropathology of Drug Abuse 2021. [DOI: 10.1007/978-3-030-60531-5_2] [Reference Citation Analysis]
18 Wu R, Li JX. Toll-Like Receptor 4 Signaling and Drug Addiction. Front Pharmacol 2020;11:603445. [PMID: 33424612 DOI: 10.3389/fphar.2020.603445] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Lucerne KE, Kiraly DD. The role of gut-immune-brain signaling in substance use disorders. Int Rev Neurobiol 2021;157:311-70. [PMID: 33648673 DOI: 10.1016/bs.irn.2020.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Doyle TM, Hutchinson MR, Braden K, Janes K, Staikopoulos V, Chen Z, Neumann WL, Spiegel S, Salvemini D. Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents. J Neuroinflammation 2020;17:314. [PMID: 33092620 DOI: 10.1186/s12974-020-01975-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]